H
Hugues de Lavallade
Researcher at University of Cambridge
Publications - 67
Citations - 3014
Hugues de Lavallade is an academic researcher from University of Cambridge. The author has contributed to research in topics: Transplantation & Internal medicine. The author has an hindex of 17, co-authored 57 publications receiving 2363 citations. Previous affiliations of Hugues de Lavallade include King's College London & Guy's and St Thomas' NHS Foundation Trust.
Papers
More filters
Journal ArticleDOI
Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib
David Marin,Alexandra Bazeos,François Xavier Mahon,Lina Eliasson,Dragana Milojkovic,Marco Bua,Jane F. Apperley,Richard Szydlo,Ritti Desai,Kasia Kozlowski,Christos Paliompeis,Victoria Latham,Letizia Foroni,Mathieu Molimard,Alistair Reid,Katy Rezvani,Hugues de Lavallade,Cristina Guallar,John M. Goldman,Jamshid S. Khorashad +19 more
TL;DR: In patients with CML treated with imatinib for some years, poor adherence may be the predominant reason for inability to obtain adequate molecular responses.
Journal ArticleDOI
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
Camille N. Abboud,Ellin Berman,Adam D. Cohen,Jorge E. Cortes,Daniel J. DeAngelo,Michael W. Deininger,Steven M. Devine,Brian J. Druker,Amir T. Fathi,Elias Jabbour,Madan Jagasia,Hagop M. Kantarjian,Jean Khoury,Pierre Laneuville,Richard A. Larson,Jeffrey H. Lipton,Joseph O. Moore,Tariq I. Mughal,Susan O'Brien,Javier Pinilla-Ibarz,Alfonso Quintás-Cardama,Jerald P. Radich,Vishnu Reddy,Charles A. Schiffer,Neil P. Shah,Paul J. Shami,Richard T. Silver,David S. Snyder,Richard Stone,Moshe Talpaz,Ayalew Tefferi,Richard A. Van Etten,Meir Wetzler,Elisabetta Abruzzese,Jane F. Apperley,Massimo Breccia,Jenny Byrne,Francisco Cervantes,Ekaterina Chelysheva,Richard E. Clark,Hugues de Lavallade,Iryna Dyagil,Carlo Gambacorti-Passerini,John M. Goldman,Ibrahim C. Haznedaroglu,Henrik Hjorth-Hansen,Tessa L. Holyoake,Brian J. P. Huntly,Philipp le Coutre,Elza Lomaia,Francois-Xavier Mahon,David Marin-Costa,Giovanni Martinelli,Jiri Mayer,Dragana Milojkovic,Eduardo Olavarria,Kimmo Porkka,Johan Richter,Philippe Rousselot,Giuseppe Saglio,Güray Saydam,Jesper Stentoft,Anna G. Turkina,Paolo Vigneri,Andrey Zaritskey,Alvaro Aguayo,Manuel Ayala,Israel Bendit,Raquel Bengió,Carlos Best,Eduardo Bullorsky,Eduardo Cervera,Carmino DeSouza,Ernesto Fanilla,David Gómez-Almaguer,Nelson Hamerschlak,José A. López,Alicia Magarinos,Luis Meillon,Jorge Milone,Beatriz Moiraghi,Ricardo Pasquini,Carolina Pavlovsky,Guillermo J. Ruiz-Argüelles,Nelson Spector,Christopher Arthur,Peter Browett,Andrew Grigg,Jianda Hu,Xiao-Jun Huang,Timothy P. Hughes,Qian Jiang,Saengsuree Jootar,Dong-Wook Kim,Hemant Malhotra,Pankaj Malhotra,Itaru Matsumura,Junia V. Melo,Kazunori Ohnishi,Ryuzo Ohno,Tapan Saikia,Anthony P. Schwarer,Naoto Takahashi,Constantine S. Tam,Tetsuzo Tauchi,Kensuke Usuki,Jianxiang Wang,Fawzi Abdel-Rahman,Mahmoud Aljurf,Ali Bazarbachi,Dina Ben Yehuda,Naeem Chaudhri,Muheez A. Durosinmi,Hossam Kamel,Vernon J. Louw,Bassam Francis Matti,Arnon Nagler,Pia Raanani,Ziad Salem +118 more
TL;DR: There is a need to (1) lower the prices of cancer drugs to allow more patients to afford them and (2) maintain sound long-term health care policies.
Journal ArticleDOI
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society
Alexander R. Lyon,Susan Dent,Susannah Stanway,Helena M. Earl,Christine Brezden-Masley,Alain Cohen-Solal,Carlo G. Tocchetti,Javid Moslehi,John D. Groarke,Jutta Bergler-Klein,Vincent Khoo,Vincent Khoo,Li Ling Tan,Markus S. Anker,Stephan von Haehling,Christoph Maack,Radek Pudil,Ana Barac,Paaladinesh Thavendiranathan,Bonnie Ky,Tomas G. Neilan,Y N Belenkov,Stuart D. Rosen,Zaza Iakobishvili,Aaron L. Sverdlov,Ludhmila Abrahão Hajjar,Ariane Vieira Scarlatelli Macedo,Charlotte Manisty,Fortunato Ciardiello,Dimitrios Farmakis,Dimitrios Farmakis,Rudolf A. de Boer,Hadi Skouri,Thomas M. Suter,Daniela Cardinale,Ronald M. Witteles,Michael G. Fradley,Joerg Herrmann,Robert F. Cornell,Ashutosh Wechelaker,Michael J. Mauro,Dragana Milojkovic,Hugues de Lavallade,Frank Ruschitzka,Andrew J.S. Coats,Petar M. Seferovic,Ovidiu Chioncel,Thomas Thum,Johann Bauersachs,M. Sol Andres,David Wright,Teresa López-Fernández,Chris Plummer,Daniel J. Lenihan +53 more
TL;DR: In this paper, the authors presented a risk stratification proformas for oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities, with the aim of improving personalised approaches to minimise the risk of cardiovascular toxicity from cancer therapies.
Journal ArticleDOI
Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7).
Catherine Cordonnier,Sigrun Einarsdottir,Simone Cesaro,Roberta Di Blasi,Malgorzata Mikulska,Christina Rieger,Hugues de Lavallade,Giuseppe Gallo,Thomas Lehrnbecher,Dan Engelhard,Per Ljungman +10 more
TL;DR: It is recommended to start crucial vaccinations with inactivated vaccines from 3 months after transplant, irrespectively of whether the patient has or has not developed graft-versus-host disease (GvHD) or received immunosuppressants.
Journal ArticleDOI
De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial
Richard E. Clark,Fotios Polydoros,Jane F. Apperley,Dragana Milojkovic,Katherine Rothwell,Christopher Pocock,Jennifer Byrne,Hugues de Lavallade,Wendy Osborne,L. G. Robinson,Stephen G. O'Brien,Lucy Read,Letizia Foroni,Mhairi Copland +13 more
TL;DR: Initial de-escalation before discontinuation might improve the success of TFR protocols, although the mechanism of its benefit is not yet clear and the findings suggest that TFR merits further study in patients with stable MMR.